Fort Collins-based Omni Bio Pharmaceutical seeking to raise $1M
FORT COLLINS – Omni Bio Pharmaceutical Inc. is seeking to raise $1 million in new debt and equity, according to a filing made with the Securities and Exchange Commission.
Officials for the company, which is developing a recombinant version of the naturally occurring human protein Alpha-1 Antitrypsin (AAT), could not be reached Monday.
Omni Bio, a spinoff of University of Colorado technology, is largely a virtual company, with chief executive Bruce Schneider and other key players spread out in different locations. But the company last year moved its official headquarters from Greenwood Village to Fort Collins to place it nearer to the offices of its primary investors.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
The company trades publicly over the counter under the ticker symbol OMBP. Shares on Monday were trading at 24 cents each, down 4 cents from Friday’s close.
FORT COLLINS – Omni Bio Pharmaceutical Inc. is seeking to raise $1 million in new debt and equity, according to a filing made with the Securities and Exchange Commission.
Officials for the company, which is developing a recombinant version of the naturally occurring human protein Alpha-1 Antitrypsin (AAT), could not be reached Monday.
Omni Bio, a spinoff of University of Colorado technology, is largely a virtual company, with chief executive Bruce Schneider and other key players spread out in different locations. But the company last year moved its official headquarters from Greenwood Village to Fort Collins to place it nearer to the…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
